Soliton Announces Second Quarter 2020 Financial Results and Business Update on Tuesday, August 11, 2020

Rhea-AI Summary

Soliton, Inc. (Nasdaq: SOLY) will report its second quarter 2020 financial results and provide a business update on August 11, 2020. The company specializes in a novel healing technology licensed from MD Anderson Cancer Center, with a focus on the Rapid Acoustic Pulse (RAP) device for tattoo removal. A conference call will occur at 8:30 a.m. ET, followed by a Q&A session. The RAP device has FDA clearance for tattoo removal but is still under investigation for other uses. A replay of the call will be available until August 18, 2020.

Positive

• FDA clearance for the RAP device for tattoo removal.
• Potential for the RAP technology to reduce costs for patients and increase profitability for practitioners.

Negative

• None.

HOUSTON, July 29, 2020 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, announced today that it will report its second quarter 2020 financial results and provide a business update on Tuesday, August 11, 2020 before the open of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Soliton's financial results at 8:30 a.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (833) 423-0479 for domestic callers and (918) 922-2373 for international callers.  The conference ID is 4287640.

A replay of the call will be available following its completion through August 18, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 4287640.

A live audio webcast of the call and an updated investor presentation will be available on the Investor Relations page of the Soliton, Inc. website, https://ir.soliton.com/. A replay of the webcast will be archived on Soliton's website for 30 days following the completion of the call.

------------------------

Join our more than 200K subscribers here to follow the Company: https://soly-investors.com

------------------------

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods.  Soliton is investigating potential additional capabilities of the RAP technology in clinical and preclinical testing, including the potential to improve the appearance of cellulite and the potential to treat keloid and hypertrophic scars by targeting the stiffened environment in the intracellular matrix. The RAP device has received 510(k) clearance for use in tattoo removal but remains investigational for use in improving the appearance of cellulite and scar treatment.

For more information about the Company, please visit: http://www.soliton.com

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Item 1A. Risk Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC on March 2, 2020 and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/soliton-announces-second-quarter-2020-financial-results-and-business-update-on-tuesday-august-11-2020-301101923.html

SOURCE Soliton, Inc.

FAQ

What date will Soliton report its Q2 2020 financial results?

Soliton will report its Q2 2020 financial results on August 11, 2020.

What is the purpose of the upcoming conference call by Soliton?

The conference call will discuss Soliton's financial results and include a Q&A session.

What is the Rapid Acoustic Pulse (RAP) device used for?

The RAP device is designed for the removal of unwanted tattoos and has received FDA clearance for this purpose.

What are the potential additional uses for the RAP technology?

Soliton is investigating the use of RAP technology for improving the appearance of cellulite and treating keloid and hypertrophic scars.